ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The Dutch nucleic acid specialist Qiagen has agreed to acquire Shenzhen PG Biotech, a Chinese developer of polymerase chain-reaction-based molecular diagnostic kits. Qiagen will buy all of PG's shares, 52% of which are held by state-owned institutions, for $14.5 million. Qiagen says the purchase is a “superb fit” with its own molecular diagnostics business. It recently acquired Artus, a German firm also focused on molecular diagnostics.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter